The Kenya Bio-Vaccine Mission Program in the Republic of Korea (23rd–30th October 2025) brought together Kenyan experts and institutions, including the Kenya BioVax Institute Limited, to benchmark Korea’s world-class vaccine research, manufacturing, and innovation ecosystem. Through visits to Celltrion Inc, the International Vaccine Institute (IVI), KAIST, the Public Contract Development and Manufacturing Organization (PCMO), and the Korea Disease Control and Prevention Agency (KDCA), the delegation—featuring BioVax leadership—explored opportunities in technology transfer, workforce training, and collaborative research to advance Kenya’s Smart Vaccine Manufacturing Facility at Konza Technopolis. The mission strengthened bilateral partnerships, reaffirmed IVI’s commitment to supporting BioVax’s vaccine production agenda, and positioned the Institute as a key driver of Kenya’s journey toward vaccine self-reliance and sustainable health innovation.
